Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.44 |
| ▸ | CCR1 | P32246 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175548 | 0.89 | NR3C1 (0.53) | NR3C1MAPK1SCN9ASCN10ACCR1 | |
| SCHEMBL4168046 | 0.80 | NR3C1 (0.72) | NR3C1SCN9ASCN10ACCR1CYP17A1 | |
| SCHEMBL4166444 | 0.80 | NR3C1 (0.57) | NR3C1SCN9ASCN10ACCR1CYP17A1 | |
| SCHEMBL4168041 | 0.79 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL4158857 | 0.79 | NR3C1 (0.80) | NR3C1CCR1CYP17A1CYP1A2 | |
| SCHEMBL4164112 | 0.78 | NR3C1 (0.82) | NR3C1CCR1CYP17A1CYP1A2 | |
| SCHEMBL14403954 | 0.78 | NR3C1 (0.82) | NR3C1CCR1CYP17A1CYP1A2 | |
| SCHEMBL4158339 | 0.77 | NR3C1 (0.76) | NR3C1SCN9ASCN10ACCR1MAPK14 | |
| SCHEMBL16422685 | 0.76 | NOTUM (0.61) | MAPK1 | |
| SCHEMBL16422984 | 0.76 | NOTUM (0.61) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170898-A1 | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | BENGTSSON MALENA | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170898-A1 | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885MAPK1 1075/4885SCN9A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.